Literature DB >> 11173614

Determination of HIV-1 Subtypes in Hungary by Synthetic Peptides Representing the V3 Loop of env.

Károly Nagy1, Attila Horváth.   

Abstract

For the determination of HIV-1 diversity and serotyping of HIV-1 subtypes, an enzyme immunoassay was developed based on synthetic peptides representing immunodominant epitopes of the V3 loop of HIV-1 subtypes A, B, C and E, respectively. Sera from 53 asymptomatic HIV-1 infected individuals were tested for their pattern of binding reactivity to the synthetic peptides. 45/52 (85%) of the sera reacted exclusively to V3 peptide representing HIV-1 B subtypes, 4/52 (7.6%) of the sera showed cross reacticity to A/B peptides and 1/52 (1.9%) of the sera reacted with both A and C peptides. No single reactivity with subtype A or E peptides have been observed. Results together with nucleotide sequence analysis of the V3 region of clinical isolates suggest that HIV-1 infection in Hungary has been induced predominantly by strains belonging to HIV-1 subtype B.

Entities:  

Year:  1996        PMID: 11173614     DOI: 10.1007/bf02904822

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.

Authors:  C Y Wang; D J Looney; M L Li; A M Walfield; J Ye; B Hosein; J P Tam; F Wong-Staal
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

2.  World Health Organization global AIDS statistics.

Authors: 
Journal:  AIDS Care       Date:  1995

3.  Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand.

Authors:  C P Pau; S Lee-Thomas; W Auwanit; J R George; C Y Ou; B S Parekh; T C Granade; D L Holloman; S Phillips; G Schochetman
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

4.  Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.

Authors:  R Cheingsong-Popov; S Lister; D Callow; P Kaleebu; S Beddows; J Weber
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

5.  [Isolation of human immunodeficiency virus from Hungarian AIDS and ARC patients].

Authors:  K Nagy; A Jan; D Bánhegyi; F Várnai
Journal:  Orv Hetil       Date:  1990-04-29       Impact factor: 0.540

6.  Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.

Authors:  E L Delwart; E G Shpaer; J Louwagie; F E McCutchan; M Grez; H Rübsamen-Waigmann; J I Mullins
Journal:  Science       Date:  1993-11-19       Impact factor: 47.728

7.  Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization.

Authors:  R Cheingsong-Popov; D Callow; S Beddows; S Shaunak; C Wasi; P Kaleebu; C Gilks; I V Petrascu; M M Garaev; D M Watts
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus.

Authors:  A Bobkov; R Cheingsong-Popov; M Garaev; A Rzhaninova; P Kaleebu; S Beddows; M H Bachmann; J I Mullins; J Louwagie; W Janssens
Journal:  AIDS       Date:  1994-12       Impact factor: 4.177

View more
  1 in total

1.  Studies on the antibodies to human herpesvirus type 6 among Hungarian patients with asymptomatic HIV infection.

Authors:  C L Maródi; A Csiszár; B Sierra-Vazquez; D Di Luca; E Barabás; K Nagy; J Ongrádi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.